{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:54:25Z","timestamp":1792634065444,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Several sclerosing agents are used to treat chronic venous diseases. Although they do not seem to differ in terms of efficacy, their safety profiles might differ.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To compare the safety profile of sclerosing agents through an analysis of the World Health Organization pharmacovigilance database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The authors performed a disproportionality analysis using the proportional reporting ratio (PRR) method to compare pharmacovigilance signals between each sclerosing agent among 6 adverse event syndromes of interest: hypersensitivity reactions, arterial thromboembolic disorders, venous thromboembolic disorders, cardiac arrhythmias, visual\/neurological disturbances, and skin ulcerations. The cutoff for signal detection was defined by a logPRR lower boundary 95% confidence interval (CI) \u22650 and number of cases <jats:italic toggle=\"yes\">n<\/jats:italic> \u22653.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Of 1,227 Individual Case Safety Reports (ICSRs) identified, after removal of ICSRs with unselected indications, the authors selected 472 reports for the analysis. The authors found that polidocanol is associated with more reporting of venous embolic\/thrombotic events (logPRR = 1.38 [95% CI 1.27\u20131.49]), ethanolamine with the higher pharmacovigilance disproportionality signal of cardiac arrhythmias (logPRR = 0.80 [95% CI 0.51\u20131.09]), and STS with more reporting of allergic reactions (logPRR = 1.79 [95% CI 1.59\u20131.98]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The safety profile of sclerosing agents significantly differs and should guide benefit-risk ratio assessment of such agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001876","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T04:23:13Z","timestamp":1552450993000},"page":"1517-1528","source":"Crossref","is-referenced-by-count":14,"title":["Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase"],"prefix":"10.1097","volume":"45","author":[{"given":"Audrey","family":"Roselli","sequence":"first","affiliation":[{"name":"Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France;"},{"name":"Clinical Pharmacology Department INSERM CIC1406, Grenoble Alpes University Hospital, Grenoble, France;"},{"name":"UMR 1042\u2013HP2, INSERM, University Grenoble Alpes, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Roustit","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department INSERM CIC1406, Grenoble Alpes University Hospital, Grenoble, France;"},{"name":"UMR 1042\u2013HP2, INSERM, University Grenoble Alpes, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blaise","sequence":"additional","affiliation":[{"name":"UMR 1042\u2013HP2, INSERM, University Grenoble Alpes, Grenoble, France;"},{"name":"Department of Vascular Medicine, Grenoble Alpes University Hospital, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department INSERM CIC1406, Grenoble Alpes University Hospital, Grenoble, France;"},{"name":"UMR 1042\u2013HP2, INSERM, University Grenoble Alpes, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jech.53.3.149","article-title":"Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study","volume":"53","author":"Evans","year":"1999","journal-title":"J Epidemiol Community Health"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/archinte.165.12.1420","article-title":"Relationships between symptoms and venous disease: the San Diego population study","volume":"165","author":"Langer","year":"2005","journal-title":"Arch Intern Med"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jvs.2004.09.027","article-title":"Revision of the CEAP classification for chronic venous disorders: consensus statement","volume":"40","author":"Ekl\u00f6f","year":"2004","journal-title":"J Vasc Surg"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejvs.2015.02.007","article-title":"Editor's choice\u2014management of chronic venous disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)","volume":"49","author":"Committee","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000445436","article-title":"Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins","volume":"98","author":"Yiannakopoulou","year":"2016","journal-title":"Pharmacology"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/DSS.0000000000000225","article-title":"Consensus for sclerotherapy","volume":"40","author":"Weiss","year":"2014","journal-title":"Dermatol Surg"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0268355513483280","article-title":"European guidelines for sclerotherapy in chronic venous disorders","volume":"29","author":"Rabe","year":"2014","journal-title":"Phlebology"},{"key":"R9-20230814","first-page":"CD001732","article-title":"Injection sclerotherapy for varicose veins","volume":"4","author":"Tisi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20230814","first-page":"CD008826","article-title":"Sclerotherapy for lower limb telangiectasias","volume":"12","author":"Schwartz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"R12-20230814","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1258\/phleb.2012.012s09","article-title":"Complications of foam sclerotherapy","volume":"27","author":"Cavezzi","year":"2012","journal-title":"Phlebology"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1258\/phleb.2011.011111","article-title":"Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders","volume":"27","author":"Rathbun","year":"2012","journal-title":"Phlebology"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20230814","first-page":"52","article-title":"Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol","volume":"28","author":"Goldman","year":"2002","journal-title":"Dermatol Surg"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.thromres.2012.03.023","article-title":"Low concentration detergent sclerosants induce platelet activation but inhibit aggregation due to suppression of GPIIb\/IIIa activation in vitro","volume":"130","author":"Parsi","year":"2012","journal-title":"Thromb Res"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ejvs.2007.07.011","article-title":"In vitro effects of detergent sclerosants on coagulation, platelets and microparticles","volume":"34","author":"Parsi","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejvs.2010.10.004","article-title":"In vitro effects of detergent sclerosants on clot formation and fibrinolysis","volume":"41","author":"Parsi","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1258\/phleb.2008.008063","article-title":"Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients","volume":"24","author":"Gillet","year":"2009","journal-title":"Phlebology"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10396-014-0606-0","article-title":"High-flow vascular malformation treatment using ultrasound-guided laser combined with polidocanol sclerotherapy","volume":"42","author":"Zhang","year":"2015","journal-title":"J Med Ultrason (2001)"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jvs.2011.05.093","article-title":"Neurological complications of sclerotherapy for varicose veins","volume":"55","author":"Sarvananthan","year":"2012","journal-title":"J Vasc Surg"},{"issue":"Suppl 1","key":"R23-20230814","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0268355513477282","article-title":"Sclerotherapy in venous malformation","volume":"28","author":"Rabe","year":"2013","journal-title":"Phlebology"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMc0707265","article-title":"Microembolism during foam sclerotherapy of varicose veins","volume":"358","author":"Ceulen","year":"2008","journal-title":"N Engl J Med"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(94)91270-X","article-title":"Reversible ischaemic neurological deficit after sclerotherapy of varicose veins","volume":"343","author":"Van der Plas","year":"1994","journal-title":"Lancet"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1258\/phleb.2010.010029","article-title":"High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy","volume":"26","author":"Frullini","year":"2011","journal-title":"Phlebology"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1524-4725.2012.02390.x","article-title":"Significant endothelin release in patients treated with foam sclerotherapy","volume":"38","author":"Frullini","year":"2012","journal-title":"Dermatol Surg"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jmv.2008.09.004","article-title":"Polidocanol induced cardiotoxicity: a case report and review of the literature [in French]","volume":"33","author":"Sylvoz","year":"2008","journal-title":"J Mal Vasc"},{"key":"R29-20230814","first-page":"153","article-title":"Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation","volume":"28","author":"Marrocco-Trischitta","year":"2002","journal-title":"Dermatol Surg"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1468-3083.2010.03873.x","article-title":"Subcutaneous injection of liquid and foamed polidocanol: extravasation is not responsible for skin necrosis during reticular and spider vein sclerotherapy","volume":"25","author":"Schuller-Petrovi\u0107","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/phleb.2009.008064","article-title":"Sclerotherapy: a study comparing polidocanol in foam and liquid form","volume":"25","author":"Uncu","year":"2010","journal-title":"Phlebology"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An Empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000001876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T20:02:25Z","timestamp":1692043345000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001876","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}